WO2019108049A2 - Composition anticancéreuse, antibactérienne de dégradation d'alcool, de cicatrisation de plaie cutanée, de régénération cutanée ou anti-asthmatique comprenant un mélange d'ions minéraux - Google Patents

Composition anticancéreuse, antibactérienne de dégradation d'alcool, de cicatrisation de plaie cutanée, de régénération cutanée ou anti-asthmatique comprenant un mélange d'ions minéraux Download PDF

Info

Publication number
WO2019108049A2
WO2019108049A2 PCT/KR2018/015205 KR2018015205W WO2019108049A2 WO 2019108049 A2 WO2019108049 A2 WO 2019108049A2 KR 2018015205 W KR2018015205 W KR 2018015205W WO 2019108049 A2 WO2019108049 A2 WO 2019108049A2
Authority
WO
WIPO (PCT)
Prior art keywords
weight
composition
skin
cancer
mineral ion
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/KR2018/015205
Other languages
English (en)
Korean (ko)
Other versions
WO2019108049A3 (fr
Inventor
김광호
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Kadesh Incoporation Ltd
Original Assignee
Kadesh Incoporation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from KR1020180086173A external-priority patent/KR101996383B1/ko
Priority claimed from KR1020180107032A external-priority patent/KR101963614B1/ko
Priority claimed from KR1020180107033A external-priority patent/KR101973198B1/ko
Priority claimed from KR1020180135373A external-priority patent/KR102022671B1/ko
Priority claimed from KR1020180152879A external-priority patent/KR102037431B1/ko
Application filed by Kadesh Incoporation Ltd filed Critical Kadesh Incoporation Ltd
Publication of WO2019108049A2 publication Critical patent/WO2019108049A2/fr
Publication of WO2019108049A3 publication Critical patent/WO2019108049A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration

Definitions

  • the present invention relates to a composition for anticancer, antimicrobial use, alcohol decomposition, skin wound healing, skin regeneration or anti-asthmatic, which comprises a mineral ion mixture as an active ingredient. More particularly, the present invention relates to a biotite, kaolinite A mixture of mineral ions including kaolinite, Montmorillonite, Serpentine, Mica, Clinochlore, Vermiculite and Muscovite, Anticancer agents, alcohol decomposing agents, skin wound healing or skin regeneration agents, and anti-asthmatic agents.
  • chemotherapeutic agents used for treating malignant tumors are mainly used, and most of them exhibit anticancer activity by inhibiting the synthesis of nucleic acids.
  • paclitaxel, docetaxel, and other compounds have been approved by the US Food and Drug Administration (EPA) for use in clinical practice and have shown effects by over-stabilizing the microtubules of cells and inhibiting normal cell division.
  • EPA US Food and Drug Administration
  • these anticancer drugs are not only cancer cells but also normal cells, especially cell division-active normal tissues, resulting in adverse effects such as gastrointestinal mucosal damage, hair loss, abdominal pain and the like.
  • Factors such as age, early menarche, late menopause, kidney, postmenopausal obesity, family history of breast cancer, radiation exposure, oral contraceptive, hormone replacement therapy, density of breast tissue, genetic variation and benign tumors of breast Are associated with increased risk of breast cancer, among which dietary breast cancer is known to account for about 35% of all breast cancer incidences.
  • Preservatives that are safely used as conventional preservatives and are commonly used in cosmetics and medicines include preservatives such as skin allergens (Andrea Counti et al., Contact, Dermatitis, 1997, 37; 35-36) and potential as environmental hormones (Edwin et al , Toxicology and applied pharmacology, 1998, 153, 12-19) and resistance to inducing resistant bacteria.
  • preservatives such as skin allergens (Andrea Counti et al., Contact, Dermatitis, 1997, 37; 35-36) and potential as environmental hormones (Edwin et al , Toxicology and applied pharmacology, 1998, 153, 12-19) and resistance to inducing resistant bacteria.
  • Most cosmetics are suitable for the growth of microorganisms, and because of chemical changes, it is easy to decay products.
  • liver disease mortality rate is very high, 23.5 per 100,000 population (37.8 males and 9.0 females), and the number of deaths in South Korea is the highest (41.1 / 100,000) and the second highest among the 50 deaths (72.4 / 100,000) , The third leading cause of death in the 30s (10 people / 100,000 people), is the leading cause of death in the Korean middle-aged population.
  • alcoholic liver disease is a disease that can occur in most of chronic overdoses.
  • Liver is a very important organ in charge of metabolism, detoxification, degradation, synthesis and secretion in our body.
  • the liver has the function of managing the energy metabolism, and metabolizes all the nutrients absorbed from food into a substance capable of producing energy, and supplies or stores the whole body.
  • the liver has a function of synthesizing, storing and distributing fat of about 2,000 kinds of enzymes, albumin, serum proteins of bile coagulation factors, bile acid, phospholipid and cholesterol.
  • the liver has a function to excrete various metabolites through the bile duct into the duodenum, and it plays an important role in maintaining our life because of its immune function.
  • the liver has detoxification and decomposition functions to detoxify drugs, toxic substances and alcohol.
  • the hepatocyte detoxification function of this liver is likely to damage the drug, toxic and alcoholic liver disease can cause.
  • Alcoholic liver disease can be divided into alcoholic fatty liver disease, alcoholic hepatitis, and alcoholic cirrhosis according to the clinical symptoms and usually occurs when drinking 60 to 80g of alcohol per day for 10 years.
  • Alcoholic fatty liver is caused by accumulation of cholesterol and triglyceride in hepatocyte due to excessive alcohol consumption, and it can be recovered soon after this week, but if it continues drinking, it develops into hepatitis.
  • Alcoholic hepatitis is a condition of hepatocellular necrosis and inflammation, and has various symptoms such as fatigue, anorexia, weight loss, jaundice, fever, right upper abdominal pain, and about 40% of the patients develop alcoholic cirrhosis do.
  • Alcoholic cirrhosis is a condition that can not be recovered to the normal liver. It has various symptoms such as systemic fatigue, loss of appetite, ascites, esophageal varices, hemorrhage, hepatic encephalopathy and coma and has a worse prognosis than liver cirrhosis due to hepatitis virus. ), 50% of deaths from end-stage liver disease are known to be due to alcohol.
  • Wound healing is a tissue response to injury and is a process of tissue regeneration that involves the coalescence of several cell types, including keratinocytes, fibroblasts, endothelial cells, macrophages, and platelets.
  • This process involves cell proliferation and migration rates, collagen deposition and remodeling, wound contraction, and angiogenesis.
  • Skin fibroblasts play an important role in the wound healing process, where tissue function and structure are restored and regenerated. This cell moves other cells towards the wound area and regulates cell division at the edge of the wound area. In addition, it is the most important cell involved in the production and remodeling of extracellular matrix, and the proliferation and migration rate of fibroblasts play an important role in the formation of granulation tissue and later healing of wounds.
  • Cell migration to the wound is important for wound healing and regeneration, embryonic development, inflammation, and immune response.
  • the wound healing process is a complicated process of skin regeneration that occurs after the tissue is damaged, and the cell movement proceeds to the following four stages.
  • Skin wound healing is a complex process in which the skin or other organ or tissue restores itself after a wound.
  • the epidermis the outermost layer
  • the dermis the inner or deep layer
  • the protective barrier breaks, the normal physiological process of skin wound healing begins immediately.
  • the health of the injured, diseases such as age and diabetes the presence of this object or necrotic tissue can affect the rate of skin wound healing. If skin wound healing is slow, there is a risk of secondary infection through the wound site.
  • incomplete control of wound dissipation in some wounds results in excessive scar formation, leaving functional and cosmetically inferior scar tissues.
  • Asthma is a lung disease characterized by chronic airway inflammation and airway hyperresponsiveness. It is caused by air pollutants, dust, allergens, and the like. Asthma is known to be more prevalent in pediatric than adult, and is increasing with the change of diet and westernization. The pathogenesis of asthma is known to be very diverse. During this period, the immune response of the Th2 (T helper type 2) type is exaggerated to increase the secretion of interluenes -4, 5, and 13, , Many inflammatory cells including eosinophils migrate and invade into lung tissue.
  • Th2 T helper type 2
  • inflammatory cells release a variety of proinflammatory and chemoattractant factors to further exacerbate the inflammatory response, increase mucin secretion in the intratracheal goblet cells, and cause airway hyperresponsiveness. Because of this series of reactions, patients with asthma show clinical symptoms such as dyspnea, cyanosis, and chest pain. Drugs currently used to treat asthma include steroids, bronchodilators, and antibiotics. Steroids and antibiotics are used in the treatment of asthma through the suppression of immune and inflammatory responses. In the case of bronchodilators, they are used by offsetting clinical symptoms such as dyspnea.
  • these drugs have antimicrobial resistance including side effects such as immunosuppression, inhibition of bone marrow production, and adverse effects in long-term use, and thus they are very limited in use as asthma treatment agents. Therefore, the development of natural products or new compounds that overcome these side effects, have less toxicity, and have excellent therapeutic effects, are constantly under development.
  • the inventors of the present invention have been studying to develop a substance safe for human body while having an effect on anticancer, antibacterial, alcohol decomposition, skin wound healing or skin regeneration, asthma prevention and treatment, biotite, kaolinite
  • a mineral ion mixture comprising Montmorillonite, Serpentine, Mica, Clinochlore, Vermiculite and Muscovite is a cancer cell Inhibiting proliferation, exhibiting excellent antimicrobial activity, having an alcohol-decomposing effect, forming a neoplastic tissue at a skin incision site, reducing scarring, and having an anti-asthmatic effect and being safe for a human body.
  • a technical problem to be solved by the present invention is to provide a composition for anti-cancer using an effective ingredient of a mineral ion mixture having excellent anti-cancer effect and human safety.
  • Another object of the present invention is to provide a method for preventing, ameliorating or treating cancer by administering the composition for cancer therapy to a subject.
  • Another object of the present invention is to provide an antimicrobial composition comprising a mineral ion mixture having excellent antibacterial activity and excellent human safety as an active ingredient.
  • Another object of the present invention is to provide an antiviral agent comprising the antimicrobial composition.
  • Another object of the present invention is to provide a composition for alcohol decomposition which comprises a mineral ion mixture having an alcoholysis effect as an active ingredient.
  • Another object of the present invention is to provide a composition for the treatment or prevention of hangover, liver function, or alcoholic liver disease comprising the composition for alcoholysis.
  • Another object of the present invention is to provide a method for preventing, ameliorating or treating alcoholic liver disease by administering the composition for alcoholysis to an individual.
  • Another object of the present invention is to provide a composition for skin wound healing and skin regeneration comprising a mineral ion mixture as an active ingredient.
  • Another object of the present invention is to provide a method for preventing skin wounds, improving or treating skin wounds and regenerating skin by administering compositions for skin wound healing and skin regeneration to individuals.
  • Another object of the present invention is to provide an anti-asthmatic composition comprising a mineral ion mixture having an anti-asthmatic effect as an active ingredient.
  • Another object of the present invention is to provide a method for preventing, ameliorating or treating asthma by administering the composition for anti-asthma.
  • the present invention provides a method for producing a biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegrad
  • the present invention provides a method for preventing, ameliorating or treating cancer by administering the anticancer composition to a subject.
  • the present invention provides a method of producing a biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegrad
  • an antiviral agent comprising the antibiotic composition.
  • the present invention provides a method of producing a biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegrad
  • the present invention provides a composition for alcohol treatment, prevention of hangover, prevention of liver function or composition for the treatment or prevention of alcoholic liver disease comprising the composition for alcoholysis.
  • the present invention provides a method for preventing, ameliorating or treating alcoholic liver disease by administering the composition for alcoholysis to an individual.
  • the present invention provides a method of producing a biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegrad
  • the present invention provides a method for preventing skin wounds, improving or treating skin wounds and regenerating skin by administering compositions for skin wound healing and skin regeneration to individuals.
  • the present invention provides a method of producing a biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegradable biodegrad
  • the present invention provides a method for preventing, ameliorating or treating asthma by administering the composition for anti-asthma.
  • the mineral ion mixture of the present invention can be used in combination with human breast cancer cell line MDA-MB-231, human liver cancer cell line HepG2, human lung cancer cell line A549, human ovarian cancer cell line OVCA 429, human blood cancer cell line HL60, human skin cancer cell line A375, Can inhibit cancer cell proliferation of cell line RCC4 (-) and human colon cancer cell line HCT116, and thus can be usefully used as an anticancer composition; Excellent antimicrobial activity against various fungi; It is effective in reducing hangover in the short term due to its excellent alcohol-decomposing effect, and is effective in improving liver function when taken over a long period of time; It is free from skin irritation and cytotoxicity, has excellent human stability, but also forms new tissue at the wound area and reduces scars, and is effective for skin wound healing and skin regeneration; It inhibited or eliminated various asthma symptoms induced by ovalbumin.
  • IL-4 a cytokine associated with Th2 was induced.
  • the composition containing the mineral ion mixture of the present invention is safe as a human body and has anticancer, antibacterial, alcohol decomposition, skin wound healing or skin regeneration and anti-asthmatic effect, so that it is useful as a pharmaceutical, cosmetic and food composition Can be used.
  • FIG. 1 is a graph showing cell viability by culturing Raw264.7 cells for 24 hours in a mineral ion mixture (puritone) treated at different concentrations.
  • FIG. 2 is a photograph of cells cultured for 24 hours in the Raw264.7 cells treated with puritone by concentration.
  • FIG. 3 is a graph showing cell viability by culturing Raw264.7 cells for 48 hours after treating puritone by concentration
  • Fig. 4 is a photograph of cells cultured for 48 hours in the Raw264.7 cells treated with puritone by concentration.
  • FIG. 5 is a graph showing the effect of suppressing proliferation of cancer cells by culturing the human breast cancer cell line MDA-MB-231 for 24 hours after treatment with puritone by concentration.
  • FIG. 6 is a photograph of cells cultured for 24 hours in a human breast cancer cell line MDA-MB-231 treated with puritone by concentration.
  • FIG. 7 is a graph showing the effect of suppressing proliferation of cancer cells by culturing the human breast cancer cell line MDA-MB-231 at a concentration of puritone by concentration for 48 hours
  • FIG. 9 is a graph showing the effect of inhibiting proliferation of cancer cells by culturing the human liver cancer cell line HepG2 for 24 hours after treatment with puritone by concentration.
  • FIG. 10 is a graph showing the effect of suppressing proliferation of cancer cells by culturing the human liver cancer cell line HepG2 at different concentrations of puritone for 48 hours.
  • FIG. 11 is a graph showing the effect of suppressing the proliferation of cancer cells by culturing the human lung cancer cell line A549 for 24 hours after treatment with puritone by concentration.
  • FIG. 12 is a graph showing the effect of inhibiting proliferation of cancer cells by culturing the human lung cancer cell line A549 at a concentration of puritone by concentration for 48 hours.
  • FIG. 13 is a graph showing the inhibitory effect of cancer cell proliferation by culturing human ovarian cancer cell line OVCA 429 for 3 days after treatment with puritone.
  • FIG. 14 is a photograph of a cell cultured for 3 days after treatment with puritone at a concentration of human ovarian cancer cell line OVCA 429.
  • FIG. 14 is a photograph of a cell cultured for 3 days after treatment with puritone at a concentration of human ovarian cancer cell line OVCA 429.
  • Fig. 15 shows the result of culturing the human ovarian cancer cell line OVCA 429 for 3 days after treatment with 100% of puritone.
  • FIG. 16 is a graph showing the effect of inhibiting cancer cell proliferation by culturing human blood cancer cell line HL60 for 2 days after treatment with puritone.
  • FIG. 17 is a graph showing the effect of inhibiting cancer cell proliferation by culturing human skin cancer cell line A375 for 2 days after treatment with puritone.
  • Fig. 18 is a photograph of a cell cultured for 2 days after treatment with puritone at a concentration of human skin cancer cell line A375.
  • 19 is a graph showing the effect of inhibiting cancer cell proliferation by culturing human renal cancer cell line RCC4 (-) for 2 days after treatment with puritone.
  • FIG. 20 is a photograph of a cell cultured for two days after treatment of the human renal cell carcinoma cell line RCC4 (-) with puritone by concentration.
  • FIG. 21 is a graph showing the effect of suppressing proliferation of cancer cells by culturing the human colon cancer cell line HCT116 for 24 hours after treatment with puritone by concentration.
  • FIG. 22 is a graph showing the effect of suppressing proliferation of cancer cells by culturing the human colon cancer cell line HCT116 for 48 hours after treatment with puritone by concentration.
  • FIG. 22 is a graph showing the effect of suppressing proliferation of cancer cells by culturing the human colon cancer cell line HCT116 for 48 hours after treatment with puritone by concentration.
  • Figure 24 shows the antimicrobial activity of puritone against Staphylococcus aureus .
  • Figure 26 shows the antimicrobial activity of puritone against Salmonella typhimurium .
  • Figure 27 shows the antimicrobial activity of puritone against Candida albicans .
  • FIG. 29 is a graph showing the result of color analysis of activity of aldehyde dehydrogenase by puritone.
  • FIG. 30 is a photograph of a cutaneous area reduction observed visually as a skin wound healing effect through an animal experiment of puritone.
  • FIG. 31 is a graph showing the cut-off area reduction by measuring the actual size as a skin wound healing effect through an animal experiment of purite.
  • WBC white blood cell
  • 33 is a graph showing neutrophil analysis results of BALF of puritone.
  • 34 is a graph showing the results of lymphocyte analysis of BALF of puritone.
  • 35 is a graph showing the results of IgE analysis of puritan BALF.
  • FIG. 36 shows changes in lung tissue due to puritone observed using H & E staining.
  • FIG. 37 shows changes in pulmonary tissue caused by puritone using PAS staining.
  • FIG. 38 shows the results of observing the degree of expression of IL-4 by puritone.
  • compositions of the present invention may be used in combination with biotite, kaolinite, montmorillonite, serpentine, mica, clinochlore, vermiculite and And a mineral ion mixture comprising Muscovite as an active ingredient.
  • the mineral ion mixture is selected from the group consisting of Brucite, Illite, Limestone, Zeolite, Orthoclase or Orthoclase feldspar, Nepheline, Palygorskite or Attapulgite, Magnesite, Sperrylite, Krennerite, Petzieite, and the like. But are not limited to, Petzite, Gibbsite, Allophane, Phlogopite, Lepidolite, Sylvanite, Glauconite, Dolomite, (Tourmaline), Carnallite, Andradite, and Humite. ≪ Desc / Clms Page number 2 >
  • an anticancer composition comprising the mineral ion mixture as an active ingredient.
  • the present invention provides a method for preventing, ameliorating or treating cancer by administering the composition for anti-cancer to the individual.
  • an antimicrobial composition comprising the mineral ion mixture as an active ingredient.
  • the present invention provides an antiviral agent comprising the above antimicrobial composition.
  • composition for alcoholysis comprising the mineral ion mixture as an active ingredient.
  • the present invention provides a composition for the treatment or prevention of hangover, liver function, or alcoholic liver disease comprising the composition for alcoholysis.
  • the present invention provides a method for preventing, ameliorating or treating alcoholic liver disease by administering the composition for alcoholysis as described above.
  • composition for skin wound healing and skin regeneration comprising the mineral ion mixture as an active ingredient.
  • the present invention provides a method for preventing, improving or treating skin wounds and regenerating skin by administering the skin wound healing and skin regeneration composition to an individual.
  • an anti-asthmatic composition comprising the mineral ion mixture as an active ingredient.
  • the present invention provides a method for preventing, ameliorating or treating asthma by regulating the composition for anti-asthma and for regenerating skin.
  • the mineral ion mixture is selected from the group consisting of Biotite, Kaolinite, Montmorillonite, Serpentine, Mica, Clinochlore, Vermiculite and Muscovite as main components and also contains Brucite, Illite, Limestone, Zeolite, For example, Orthoclase or Orthoclase feldspar, boehmite, Nepheline, Palygorskite or Attapulgite, Magnesite, Such as Sperrylite, Krennerite, Petzite, Gibbsite, Allophane, Phlogopite, Lepidolite, Sylvanite, Glauconite, dolomite (Dolo mite, Tourmaline, Carnallite, Andradite and Humite.
  • the mineral ion mixture is referred to as "purite" .
  • the mineral ion mixture comprises 15 to 25% by weight of kaolinite, 12 to 23% by weight of biotite, 15 to 25% by weight of montmorillonite, 10 to 13% by weight of serpentine, From 3 to 5% by weight of vermiculite, from 2 to 4% by weight of moscobite, from 2 to 5% by weight of clinocole, from 1 to 3% by weight of brucite, from 1 to 3% by weight of ilite, From 1 to 3% by weight of stones, from 0.5 to 1.5% by weight of zeolites, from 0.5 to 1.5% by weight of oligoclays or oloclayspull spores, from 0.8 to 1.0% by weight of boehmite, from 0.7 to 0.9% by weight of nephelins, 0.7 to 0.9% by weight of atropulgite, 0.6 to 0.8% by weight of magnesium, 0.5 to 0.7% by weight of spearylite, 0.5 to 0.7% by weight of crenellite,
  • Puritone is a natural, 100% mineral substance that has been researched and developed in the United States and Korea based on mineral medicine for more than 20 years. It has been approved by the US Food and Drug Administration (FDA) for its safety in all parts of the human body (eye, liver, skin) and its approval as a generic medicinal product (NDC) through its component analysis, toxicity analysis and nutritional analysis. Currently, there are 5 generic drugs. Puriton Eye Relief Drop, facial treatment, skin treatment, first-aid treatment such as burn-up, and women's clean treatment.
  • FDA US Food and Drug Administration
  • NDC generic medicinal product
  • Puriton Eye Relief Drop facial treatment, skin treatment, first-aid treatment such as burn-up, and women's clean treatment.
  • Puriton Eye Drop is known to have high therapeutic efficacy against dry eye syndrome, and is effective in treating diseases like cataracts, glaucoma, and insomnia, which are close to incurable diseases.
  • Puriton Intimate Disinfection Spray is a new concept medicine with maximal therapeutic efficacy by completely capturing the bacteria of the disease from vaginitis and cystitis which are mostly women's deep troubles and general hemorrhoids. can do.
  • a commercially available liquid form may be purchased or used directly.
  • purite is a natural mineral, which can be produced by using minerals such as kaolinite, bentonite, zeolite, calcium carbonate, and mica, which are clay materials.
  • the raw material is subjected to a grinding process to process the desired fine nano-particle minerals.
  • the pulverization may be carried out in a dry or wet process or a sequential mixing process.
  • the productivity of fine fine particles is low, and fine particles can be obtained in stages, but there is a limit in mass production and precision is poor.
  • the wet process can produce very fine and precise particles that can obtain fine powder by applying a suitable amount of water to the ball mill, .
  • the particle size of the minerals used for the preparation of the purite liquid phase is very fine powder of 5000 mesh (2 ⁇ m or less) corresponding to the nanoparticles.
  • the raw materials of puritone are mainly used as raw materials for food and pharmaceuticals, and stabilized clay minerals containing montmorillonites or bentonite, which contain many kinds of colloidal minerals.
  • the major elements of clay minerals are Si, Al, Na, K, and Ti, and trace elements are Fe, Ca, S, Mg, Ce, La, Zr, and P.
  • Bioceramic powders are Fe 2 O 3 , TiO 2 , Na 2 O, SiO 2 , P 2 O 5 , CeO 2 , K 2 O, MgO, and the like.
  • the product is a composite material containing a lot of trace minerals that are refined in a colloidal state after crushing clay minerals, which are montmorillonite (or bentonite), to a fine particle size. And a colloidal trace minerals minerals that are much smaller in particle size than blood cells.
  • clay minerals recognized in Medical Mineralogy as clay minerals are the main source of purite.
  • the pulverized minerals of the wet-pulverized nanoparticles are put into a closed open type mixer by putting an appropriate amount of mineral powder and distilled water into a high-temperature and high-pressure processing apparatus. It is a process of dissolving ionized minerals essential to the human body by reacting at a high temperature with the minerals and water which are added by applying heat of 100-300 °C or more. A large amount of mineral minerals are obtained. Minerals are extracted and then subjected to a mineral precipitation process. The duration of the process affects the particle size of the ionized minerals in the liquid phase. Approximately, the aging process requires aging time of 24 hours to a week or more depending on the desired product.
  • a filtering process is performed to separate the colloidal liquid phase and the fine powder of the precipitated minerals.
  • a precise filtering process can be used to produce an aqueous solution of the separated purite minerals.
  • an anticancer composition comprising the mineral ion mixture as an active ingredient.
  • the anticancer composition comprising the mineral ion mixture in the present invention may be a pharmaceutical composition or a food composition.
  • the cancer is exemplified by thyroid cancer, stomach cancer, colon cancer, lung cancer, ovarian cancer, breast cancer, rectal cancer, liver cancer, prostate cancer, pancreatic cancer, gallbladder cancer, blood cancer, skin cancer, kidney cancer or bile duct cancer. It is not.
  • the anticancer composition of the present invention comprises 17 wt% of montmorillonite, 23 wt% of kaolinite, 14 wt% of biotite, 12 wt% of serpentine, By weight of bismuth chloride, 4% by weight of vermiculite, 3% by weight of muskobite, 3% by weight of clinocore, 2% by weight of brucite, 2% by weight of dilite, 2% by weight of limestone, 1% by weight of oleic acid, 0.5% by weight of boehmite, 0.8% by weight of nephelin, 0.8% by weight of paliquochekate or atropulgite, 0.7% by weight of magnetite, 0.6% by weight of spearylite, 0.6 wt% of light, 0.5 wt% of petzite, 0.4 wt% of gibbsite, 0.4 wt% of allophane, 0.4 wt% of floplight, 0.3 wt% of light, 0.5 w
  • the anticancer composition of the present invention may contain 0.005 to 50 wt%, more preferably 0.01 to 30 wt%, and most preferably 0.1 to 10 wt% of the mineral ion mixture based on the total weight of the composition.
  • the content of the mineral ion mixture is less than 0.005 wt%, the cancer cell proliferation inhibitory effect of the present invention can not be obtained.
  • the content of the mineral ion mixture is more than 50 wt%, the effect is not proportional to the increase of the content, And the stability of the shape is not ensured.
  • the anticancer composition containing the mineral ion mixture of the present invention has the ability to inhibit proliferation of cancer cells and is safe for human body as a natural substance.
  • the mineral ion mixture is selected from human breast cancer cell line MDA-MB-231, human liver cancer cell line HepG2, human lung cancer cell line A549, human ovarian cancer cell line OVCA 429, human blood cancer cell line HL60, human skin cancer cell line A375, (-) and the human colon cancer cell line HCT116, respectively.
  • the present invention provides a method for preventing, ameliorating or treating cancer by administering the composition for anti-cancer to the individual.
  • an antimicrobial composition comprising the mineral ion mixture as an active ingredient.
  • the antimicrobial composition comprising the mineral ion mixture in the present invention may be a pharmaceutical composition or a cosmetic composition.
  • the present invention provides an antiviral agent comprising the above antimicrobial composition.
  • antimicrobial refers to the ability to resist bacteria and refers to all mechanisms that are performed to defend against the action of microorganisms such as bacteria, fungi, yeast, and the like. These antimicrobial effects lead to preservative effects that prevent microbial spoilage.
  • the antimicrobial composition of the present invention comprises 20 wt% of biotite, 17 wt% of kaolinite, 16 wt% of montmorillonite, 12 wt% of serpentine, 4 weight% of clinocole, 4 weight% of vermiculite, 3 weight% of moscobite, 2 weight% of brucite, 2 weight% of ilite, 2 weight% of limestone, 1 weight of zeolite, 1% by weight of oleic acid, 0.5% by weight of boehmite, 0.8% by weight of nephelin, 0.8% by weight of paliquochekate or atropulgite, 0.7% by weight of magnetite, 0.6% by weight of spearylite, 0.6 wt% of light, 0.5 wt% of petzite, 0.4 wt% of gibbsite, 0.4 wt% of allophane, 0.4 wt% of floplight, 0.3 wt% of rec
  • the antimicrobial composition of the present invention may contain 0.005 to 50 wt%, more preferably 0.01 to 30 wt%, and most preferably 0.1 to 10 wt% of the mineral ion mixture based on the total weight of the composition. If the content of the mineral ion mixture is less than 0.005% by weight, the antimicrobial effect of the present invention can not be obtained. If the content of the mineral ion mixture exceeds 50% by weight, the effect may not be proportional to the content, There is a problem that the stability of the shape is not ensured.
  • composition for alcoholysis comprising the mineral ion mixture as an active ingredient.
  • the present invention provides a composition for alcohol treatment, prevention of liver function, or a composition for the treatment or prevention of alcoholic liver disease comprising the composition for alcoholysis.
  • the composition for alcoholysis comprising a mineral ion mixture in the present invention may be a pharmaceutical composition or a food composition.
  • alcoholic liver diseases include, but are not necessarily limited to, alcoholic fatty liver disease, alcoholic hepatitis, or alcoholic cirrhosis.
  • the antimicrobial composition of the present invention comprises 24% by weight of montmorillonite, 16% by weight of kaolinite, 15% by weight of biotite, 11% by weight of serpentine, By weight of bismuth chloride, 4% by weight of vermiculite, 3% by weight of muskobite, 3% by weight of clinocore, 2% by weight of brucite, 2% by weight of dilite, 2% by weight of limestone, 1% by weight of oleic acid, 0.5% by weight of boehmite, 0.8% by weight of nephelin, 0.8% by weight of paliquochekate or atropulgite, 0.7% by weight of magnetite, 0.6% by weight of spearylite, 0.6 wt% of light, 0.5 wt% of petzite, 0.4 wt% of gibbsite, 0.4 wt% of allophane, 0.4 wt% of floplight, 0.3 wt% of rec
  • the composition for alcoholysis of the present invention may contain 0.005 to 50 wt%, more preferably 0.01 to 30 wt%, and most preferably 0.1 to 10 wt% of a mineral ion mixture based on the total weight of the composition . If the content of the mineral ion mixture is less than 0.005% by weight, the alcohol decomposition effect of the present invention can not be obtained. If the content of the mineral ion mixture is more than 50% by weight, the effect may not be proportional to the content, There is a problem that the stability of the shape is not ensured.
  • the mineral ion mixture is excellent in the alcohol decomposing effect and can exhibit the hangover resolution effect in the short term, and it is expected that the long-term administration will be effective for improving the liver function.
  • the present invention provides a method for preventing, ameliorating or treating alcoholic liver disease by administering the composition for alcoholysis as described above.
  • composition for promoting skin wound healing or skin regeneration comprising the mineral ion mixture as an active ingredient.
  • the skin wound healing or skin regeneration promoting composition comprising a mineral ion mixture in the present invention may be a pharmaceutical composition or a cosmetic composition.
  • wound means a physical rupture of continuity or completeness of tissue structure
  • skin wound healing means restoration of tissue integrity. This may mean a partial or complete restoration of tissue integrity, and thus wound treatment refers to the promotion, improvement, progression, acceleration or progress of one or more steps or processes involved in the skin wound healing process.
  • the wound may be any internal wound or external wound, particularly a skin wound, where the external structural integrity of the skin is maintained, such as, for example, bruising or internal ulceration, and thus the tissue may be internal or external body tissue.
  • the tissue is skin (e.g., human skin) and the wound may be a skin wound, such as a dermal or epidermal wound.
  • skin regeneration is a tissue regeneration process for damage, which includes chemotaxis, differentiation and replication of cells, synthesis of matrix proteins, And the rest of the biological process.
  • the types of wounds to which the skin wound healing or skin regeneration composition of the present invention can be applied include, but are not limited to, veneer wounds and lacerations, surgical incisions or wounds, punctures, grazes, scratched wounds, (Eg, pressure sores), pressure sores (eg diaper rashes, frictional blisters), pressure ulcers (eg pressure sores or windows), wounds caused by heat (direct or indirect sources of heat, Bacterial or fungal infections), ulcers, chronic wounds (including, but not limited to, burns), chemical wounds (such as acid or alkaline burns) or open or intact boils, skin rashes, scratches and acne -Related injuries such as lower leg and foot ulcers, venous leg ulcers, and pressure ulcers).
  • veneer wounds and lacerations surgical incisions or wounds, punctures, grazes, scratched wounds, (Eg, pressure sores), pressure sores (eg diaper rashes, frictional blisters), pressure ulcers
  • the skin wound healing or skin regeneration promoting composition of the present invention comprises 24% by weight of montmorillonite, 16% by weight of kaolinite, 15% by weight of biotite, 11 weight%, mica 8 weight%, vermiculite 4 weight%, moscobite 3 weight%, clinocole 3 weight%, brucite 2 weight%, ilite 2 weight%, limestone 2 weight%, zeolite 1% by weight of silica gel, 1% by weight of oligo-clay or oloclayspherd spar, 0.9% by weight of boehmite, 0.8% by weight of nephelin, 0.8% by weight of paliquochetite or atropulgite, 0.7% 0.6% by weight of crenellite, 0.5% by weight of petzite, 0.4% by weight of gibbsite, 0.4% by weight of allophane, 0.4% by weight of floplight, 0.3% by weight of recrystallized silica, 0.3% 0.3% by weight
  • the skin wound healing or skin regeneration promoting composition of the present invention may contain 0.005 to 50 wt.%, More preferably 0.01 to 30 wt.%, Most preferably 0.1 to 10 wt.% Of a mineral ion mixture based on the total weight of the composition. As shown in FIG. If the content of the mineral ion mixture is less than 0.005% by weight, the effect of promoting skin wound healing and skin regeneration, which is the object of the present invention, can not be obtained. If the content exceeds 50% by weight, the effect is proportionate There is a problem that the stability of the shape can not be secured.
  • the mineral ion mixture is free from skin irritation and cytotoxicity and has excellent human stability, but also forms new tissue at the wound area and reduces scars to provide cosmetic or pharmaceutical compositions for skin wound healing and skin regeneration It can be safely used as an active ingredient.
  • the present invention provides a method of preventing skin wounds, improving or treating skin wounds and regenerating skin by administering compositions for skin wound healing and skin regeneration to individuals.
  • composition for preventing or treating asthma comprising the mineral ion mixture as an active ingredient.
  • the composition for preventing or treating asthma comprising a mineral ion mixture in the present invention may be a pharmaceutical composition or a food composition.
  • the term "asthma” refers to a disease in which the bronchus in the lung is very sensitive, sometimes the bronchus narrows, and the breathing, It is caused by allergic diseases.
  • the most common symptoms of asthma include dyspnea, cough, wheezing (whez breathing), a symptom reliever (bronchodilator) that alleviates the narrowed bronchus in a short time, or a disease modifier that prevents asthma attacks by inhibiting bronchial allergic inflammation Anti-inflammatory agents, and leukotriene modulators).
  • the asthma may be, but not limited to, bronchial asthma, allergic asthma, atopic asthma, non-atopic asthma, exercise induced asthma, aspirin asthma, cardiogenic asthma or alveolar asthma.
  • the composition for preventing or treating asthma according to the present invention comprises 19% by weight of kaolinite, 18% by weight of biotite, 17% by weight of montmorillonite, 12% % Mica, 4% by weight of vermiculite, 3% by weight of moscobite, 3% by weight of clinocore, 2% by weight of brucite, 2% by weight of ilite, 2% by weight of limestone and 1% by weight of zeolite 1% by weight, oloclase or oloclayspherd spar, 0.9% by weight boehmite, 0.8% by weight nephelin, 0.8% by weight of palycorhkate or atropulgite, 0.7% by weight of magnesium, 0.6% by weight of spearylite 0.6% by weight of crenellite, 0.5% by weight of petzite, 0.4% by weight of gibbsite, 0.4% by weight of allophane, 0.4% by weight of floplight, 0.3% by weight of recry
  • Kaolinite A1 2 Si 2 O 5 ( OH) 4) 19 Bio-tight (KFe 3 (AlSi 3 O 10 ) (OH) 2) 18 ((Na, Ca) 0.3 (Al, Mg) 2 Si 4 O 10 (OH) 2n (H 2 O)) 17 Surfentin (Mg, Fe) 3 Si 2 O 5 (OH) 4 ) 12
  • Mica AB 2- 3 (X, Si ) 4 O 10 (O, F, OH) 2) 8 (Mg, Fe, Al) 3 (Al, Si) 4 O 10 (OH) 2 .4H 2 O) 4 Muscovite (KAl 2 (AlSi 3 O 10 ) (F, OH) 2 ) 3 (Mg, Fe, Al) 6 (Si, Al) 4 O 10 (OH) 8 ) 3 Brucite (Mg (OH) 2 ) 2 Illite (KAl 1.
  • the composition for preventing or treating asthma according to the present invention contains 0.005 to 50% by weight, more preferably 0.01 to 30% by weight, most preferably 0.1 to 10% by weight, based on the total weight of the composition, of a mineral ion mixture can do. If the content of the mineral ion mixture is less than 0.005% by weight, the anti-asthmatic effect of the present invention can not be obtained. If the content of the mineral ion mixture is more than 50% by weight, the effect may not be proportional to the content, There is a problem that the stability of the shape is not ensured.
  • the mineral ion mixture can reduce the number of inflammatory cells around the bronchi or the blood vessels or reduce the mucus secretion of the bronchial goblet cells.
  • Bronchoalveolar lavage was performed in patients with asthma, and airway inflammation was confirmed.
  • lymphocytes, mast cells, eosinophils and activated macrophages were increased in bronchoalveolar lavage fluid.
  • asthma is generalized as airway inflammation disease, and most inflammatory cells are activated and secrete various mediators to induce asthma, and reduction of inflammatory cells is known to be related to the treatment of asthma (Haley KJ , et al., Am J Respir Crit Care Med, 1998; 158: 565-72).
  • asthma is a kind of asthmatic symptom, because airway stenosis and infiltration of inflammatory cells into the bronchi, goblet cells are formed, secretion of mucus is prominent, and collagen deposition is prominent. It is known.
  • the present invention provides a method for preventing, ameliorating or treating asthma by administering the composition for anti-asthma to the individual.
  • the above-mentioned "active ingredient” means a component that exhibits the desired activity alone or can exhibit activity together with a carrier which is itself inactive.
  • a pharmaceutical composition comprising a mineral ion mixture as an active ingredient.
  • the pharmaceutical composition may be any one selected from the group consisting of tablets, pills, powders, granules, capsules, suspensions, solutions, emulsions, syrups, sterilized aqueous solutions, nonaqueous solvents, suspensions, emulsions, And may be oral or parenteral formulations of various forms.
  • a diluent or excipient such as a filler, an extender, a binder, a wetting agent, a disintegrant, or a surfactant is usually used.
  • Solid formulations for oral administration include tablets, pills, powders, granules, capsules, and the like, which may contain one or more excipients such as starch, calcium carbonate, sucrose or lactose lactose, gelatin and the like. In addition to simple excipients, lubricants such as magnesium stearate, talc, and the like may also be used.
  • Liquid preparations for oral administration include suspensions, solutions, emulsions, syrups and the like.
  • excipients such as wetting agents, sweeteners, fragrances, preservatives and the like may be included in addition to water and liquid paraffin, which are simple diluents commonly used. have.
  • Formulations for parenteral administration include sterilized aqueous solutions, non-aqueous solutions, suspensions, emulsions, freeze-dried preparations, and suppositories.
  • Propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used as the non-aqueous solvent and suspension agent.
  • Examples of the suppository base include witepsol, macrogol, tween 61, cacao paper, laurin, glycerogelatin and the like.
  • composition of the present invention may be administered in a pharmaceutically effective amount.
  • pharmaceutically effective amount as used herein means an amount sufficient to treat a disease at a reasonable benefit / risk ratio applicable to medical treatment, and the effective dose level will vary depending on the species and severity, age, sex, , The activity of the drug, the sensitivity to the drug, the time of administration, the route of administration and rate of release, the duration of the treatment, factors including co-administered drugs, and other factors well known in the medical arts.
  • the composition of the present invention may be administered as an individual therapeutic agent or in combination with another therapeutic agent, and may be administered sequentially or simultaneously with a conventional therapeutic agent. And can be administered singly or multiply.
  • administering means introducing the pharmaceutical composition of the present invention into a subject by any suitable method, and the administration route can be administered through various routes of oral or parenteral administration as long as it can reach the target tissues .
  • the specific therapeutically effective amount for a particular patient will depend upon the nature and extent of the reaction to be achieved, the particular composition, including whether or not other agents are used, the age, weight, Sex and diet of the patient, the time of administration, the route of administration and the rate of administration of the composition, the duration of the treatment, the drugs used or concurrently used with the specific composition, and similar factors well known in the medical arts.
  • the preferred dosage of the composition of the present invention will depend on the condition and the weight of the patient, the severity of the disease, the type of drug, the route of administration and the period of time, and the appropriate total daily dose can be determined by treatment However, it is generally administered in an amount of 0.001 to 1000 mg / kg, preferably 0.05 to 200 mg / kg, more preferably 0.1 to 100 mg / kg, once or several times a day.
  • the composition is not particularly limited as long as it is a target object, and any object can be applied.
  • any non-human animal such as a monkey, a dog, a cat, a rabbit, a guinea pig, a rat, a mouse, a cattle, a sheep, a pig, Including but not limited to, For example, by oral, rectal or intravenous, intramuscular, subcutaneous, intra-uterine dural or intracerebral injection.
  • a cosmetic composition comprising a puritone as an active ingredient.
  • the cosmetic composition according to one embodiment of the present invention may contain, in addition to the friton as an active ingredient, conventional additives such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavors, May be further added.
  • conventional additives such as antioxidants, stabilizers, solubilizers, vitamins, pigments and flavors, May be further added.
  • the cosmetic composition of the present invention can be prepared into any of the formulations conventionally produced in the art and can be used as a solution, a suspension, an emulsion, a paste, a gel, a cream, a lotion, a powder, a soap, , Oil, powder foundation, emulsion foundation, wax foundation and spray, but is not limited thereto. More specifically, it can be prepared as a nutritional cream, a convergent lotion, a soft lotion, a lotion, an essence, a nutritional gel or a massage cream.
  • the formulation of the present invention is a paste, cream or gel
  • tosse When the formulation of the present invention is a powder or a spray, tosse, talc, silica, aluminum hydroxide, calcium silicate or polyamide powder may be used as a carrier component.
  • a spray in particular, chlorofluorohydrocarbons, propane / Propane or dimethyl ether.
  • a solvent, a solubilizing agent or an emulsifying agent is used as a carrier component, and examples thereof include water, ethanol, isopropanol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, , 3-butyl glycol oil, glycerol aliphatic ester, polyethylene glycol or sorbitan fatty acid esters.
  • the formulation of the present invention is a suspension
  • a carrier such as water, a liquid diluent such as ethanol or propylene glycol, a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Castellulose, aluminum metahydroxide, bentonite, agar or tracert, etc.
  • a suspending agent such as ethoxylated isostearyl alcohol, polyoxyethylene sorbitol ester and polyoxyethylene sorbitan ester, Castellulose, aluminum metahydroxide, bentonite, agar or tracert, etc.
  • the carrier component may include aliphatic alcohol sulfate, aliphatic alcohol ether sulfate, sulfosuccinic acid monoester, isethionate, imidazolinium derivative, methyltaurate, sarcosinate, fatty acid amide Ether sulfates, alkylamidobetaines, aliphatic alcohols, fatty acid glycerides, fatty acid diethanolamides, vegetable oils, lanolin derivatives or ethoxylated glycerol fatty acid esters.
  • a food composition comprising a mineral ion mixture as an active ingredient.
  • the composition of the present invention When the composition of the present invention is used as a food, the composition may be added as it is or may be used in combination with other health food, health functional food or health functional food component, and may be appropriately used according to a conventional method.
  • the amount of the active ingredient to be mixed can be appropriately determined depending on the purpose of use.
  • the composition of the present invention may be added in an amount of preferably not more than 15 parts by weight, more preferably not more than 10 parts by weight, based on the raw material, in the production of food or beverage.
  • the amount may be less than the above range, and since there is no problem in terms of stability, the active ingredient may be used in an amount in the above range.
  • composition of the present invention is not particularly limited, and examples thereof include dairy products including meat, sausage, bread, chocolate, candy, snack, confectionery, pizza, ramie noodle, other noodles, gum, ice cream , Various soups, beverages, tea, drinks, alcoholic beverages, and vitamin complexes, and may include all foods in the conventional sense, and foods used as feed for animals.
  • the food composition of the present invention when used in the form of a drink, it may contain various sweetening agents, flavoring agents, or natural carbohydrates as additional components such as ordinary beverages.
  • the natural carbohydrates may be polysaccharides such as disaccharides such as monosaccharides such as glucose and fructose, maltose, sucrose, dextrin, cyclodextrins, and sugar alcohols such as xylitol, sorbitol and erythritol.
  • the ratio of the natural carbohydrate is not limited thereto, but may be about 0.01 to 0.04 g, and more preferably 0.02 to 0.03 g per 100 ml of the composition of the present invention.
  • the sweeteners may be natural sweeteners such as tau martin and stevia extract, and synthetic sweeteners such as saccharin and aspartame.
  • the food composition of the present invention may contain various nutrients, vitamins, electrolytes, flavors, colorants, pectic acids and salts thereof, alginic acid and its salts, organic acids, protective colloid thickening agents, pH adjusting agents, stabilizers, preservatives, , A carbonating agent used in carbonated drinks, and the like. It may also contain flesh for the production of natural fruit juices, fruit juice drinks and vegetable drinks.
  • the puritone of the present invention is a natural substance which is harmless to the human body, has little toxicity and side effects, and can be safely used for a long time, and can be safely applied to pharmaceuticals, cosmetics and food compositions as described above.
  • MTT (3- [4,5-dimethylthiazol-2-yl] -2,5-diphinyltetrazolium bromide) solution (storage concentration: 5 mg / ml) was added and further reaction was induced for 3 hours.
  • the cell viability was calculated from the OD value obtained by measuring the absorbance at 570 nm using a spectrophotometer (Molecular Device, CA, USA) in which the amount of MTT reduced to formazan was measured.
  • FIG. 1 is a graph showing the cell survival rate by culturing Raw264.7 cells in a concentration-dependent manner for 24 hours.
  • FIG. 2 is a graph showing the cell survival rate of Raw264.7 cells treated with puritone It is a photograph. As shown here, cell proliferation was observed at 0.5 to 25% for 24 hours in the cell culture, and there was little decrease in cell survival rate in RAW264.7 cells, and it was confirmed that there was no cytotoxicity.
  • FIG. 3 is a graph showing cell viability by culturing Raw264.7 cells in a concentration-dependent manner at a concentration of puritone for 48 hours.
  • FIG. 4 is a graph showing the cell viability of Raw264.7 cells after 48 hours of treatment with puritone It is a photograph. As shown here, cell proliferation was observed at 0.5 to 25% for 48 hours in the cell culture, and there was little decrease in cell survival rate in RAW264.7 cells, confirming no cytotoxicity.
  • the human breast cancer cell line MDA-MB-231 was suspended in DMEM medium (Dulbecco's Modified Eagle Medium, Gibco) supplemented with 10% fetal bovine serum and 1% penicillin at a concentration of 1 x 10 4 / Inoculated on a 96-well plate and allowed to attach for 12 hours. Puritone was treated with concentrations (0, 1, 2, 5, 10, 50, 100 ⁇ l / 200 ⁇ l (0 - 55%)) and cultured for 24 and 48 hours.
  • DMEM medium Dulbecco's Modified Eagle Medium, Gibco
  • MTT (3- [4,5-dimethylthiazol-2-yl] -2,5-diphinyltetrazolium bromide) solution (storage concentration: 5 mg / ml) was added and further reaction was induced for 3 hours.
  • the cell viability was calculated from the OD value obtained by measuring the absorbance at 570 nm using a spectrophotometer (Molecular Device, CA, USA) in which the amount of MTT reduced to formazan was measured.
  • FIG. 5 is a graph showing the effect of inhibiting the proliferation of cancer cells by culturing the human breast cancer cell line MDA-MB-231 for 24 hours after treatment with puritone by concentration;
  • FIG. 6 is a graph showing the effect And then cultured for 24 hours. As shown here, it was found that the cell growth inhibition effect was 25 to 50% for 24 hours.
  • FIG. 7 is a graph showing the effect of inhibiting proliferation of cancer cells by culturing the human breast cancer cell line MDA-MB-231 at a concentration of puritone by concentration for 48 hours
  • FIG. 8 is a graph showing the effect of suppressing the proliferation of human breast cancer cell line MDA- And then cultured for 48 hours. As shown here, it was found that the cell growth inhibitory effect was 25 to 50% during cell culture.
  • Puritone was tested by the following method in order to confirm the inhibitory effect of cancer cell growth on liver cancer cell line HepG2.
  • Human liver cancer cell line HepG2 was suspended in DMEM medium (Dulbecco's Modified Eagle Medium, Gibco) supplemented with 10% fetal bovine serum and 1% penicillin at a concentration of 1 x 10 4 / ml, And inoculated for 12 hours. Puritone was treated with concentration (0, 1, 2, 5, 10, 50, 100, 150 ⁇ l / 200 ⁇ l (0 - 75%)) and cultured for 24 hours and 48 hours.
  • DMEM medium Dulbecco's Modified Eagle Medium, Gibco
  • concentration 0., 1, 2, 5, 10, 50, 100, 150 ⁇ l / 200 ⁇ l (0 - 75%)
  • MTT (3- [4,5-dimethylthiazol-2-yl] -2,5-diphinyltetrazolium bromide) solution (storage concentration: 5 mg / ml) was added and further reaction was induced for 3 hours.
  • the cell viability was calculated from the OD value obtained by measuring the absorbance at 570 nm using a spectrophotometer (Molecular Device, CA, USA) in which the amount of MTT reduced to formazan was measured.
  • FIG. 9 is a graph showing the effect of inhibiting proliferation of cancer cells by culturing the human liver cancer cell line HepG2 for 24 hours after treatment with puritone by concentration. As shown here, it was found that the cell growth inhibition effect was 50 to 70% for 24 hours.
  • FIG. 10 is a graph showing the effect of suppressing proliferation of cancer cells by culturing the human liver cancer cell line HepG2 at different concentrations of puritone for 48 hours. As shown here, it was found that the cell growth inhibition effect was 50 to 75% for 48 hours.
  • Puritone was tested by the following method to confirm the inhibitory effect of cancer cell line A549 on cancer cell proliferation.
  • Human lung cancer cell line A549 was suspended in RPMI 1640 medium supplemented with 10% fetal bovine serum (Fetal Bovine Serum) and 1% penicillin at a concentration of 1x10 4 / ml, and 200 ⁇ l of each was inoculated in a 96-well plate and adhered for 12 hours . Puritone was treated with concentration (0, 1, 2, 5, 10, 50, 100, 150 ⁇ l / 200 ⁇ l (0 - 75%)) and cultured for 24 hours and 48 hours.
  • MTT (3- [4,5-dimethylthiazol-2-yl] -2,5-diphinyltetrazolium bromide) solution (storage concentration: 5 mg / ml) was added and further reaction was induced for 3 hours.
  • the cell viability was calculated from the OD value obtained by measuring the absorbance at 570 nm using a spectrophotometer (Molecular Device, CA, USA) in which the amount of MTT reduced to formazan was measured.
  • FIG. 11 is a graph showing the effect of suppressing the proliferation of cancer cells by culturing the human lung cancer cell line A549 for 24 hours after treatment with puritone by concentration. As shown here, it was found that the cell growth inhibition effect was 50 to 70% for 24 hours.
  • FIG. 12 is a graph showing the effect of inhibiting proliferation of cancer cells by culturing the human lung cancer cell line A549 at a concentration of puritone by concentration for 48 hours. As shown here, it was found that the cell growth inhibition effect was 50 to 75% for 48 hours.
  • Puritone inhibited cancer cell proliferation in ovarian cancer cell OVCA 249 by the following method.
  • FIG. 13 is a graph showing inhibitory effect on cancer cell proliferation by culturing human ovarian cancer cell line OVCA 429 for 3 days after treatment with puritone
  • FIG. 14 is a graph showing the effect of puritone treatment on human ovarian cancer cell line OVCA 429 Cell culture. As shown here, the puritone treated at a concentration of 70% showed 99% inhibition of OVCA429 cell growth.
  • Fig. 15 shows the result of culturing the human ovarian cancer cell line OVCA 429 for 3 days after treatment with 100% of puritone. As shown here, the puritone showed 99% inhibition of OVCA429 cell growth.
  • FIG. 16 is a graph showing the inhibitory effect of cancer cell proliferation by culturing human blood cancer cell line HL60 for 2 days after treatment with puritone. As shown here, HL60 cell growth inhibition was 70% at 50% puritone treatment and 99% HL60 cell growth inhibition at 70% puritone treatment.
  • FIG. 17 is a graph showing the inhibitory effect of cancer cell proliferation inhibition by culturing human skin cancer cell line A375 for 2 days after treatment with puritone.
  • FIG. 19 is a graph showing the effect of puritone treatment on human skin cancer cell line A375 It is a photograph. As shown here, A375 cell growth inhibition was 20% at 50% puritone treatment and 99% HL60 cell growth inhibition at 70% puritone treatment.
  • Puritone inhibited the cancer cell proliferation inhibition in the renal cancer cell RCC4 (-) as described above.
  • FIG. 19 is a graph showing the cancer cell proliferation inhibitory effect by culturing the human renal cell carcinoma cell line RCC4 (-) for 2 days after treatment with puritone.
  • FIG. 20 is a graph showing the effect of treating the human renal cancer cell line RCC4 And then cultured for 2 days. As shown here, the inhibition of RCC4 (-) cell growth by 70% puritone treatment was 99%.
  • FIG. 21 is a graph showing the effect of suppressing proliferation of cancer cells by culturing the human colon cancer cell line HCT116 for 24 hours after treatment with puritone by concentration. As shown here, the inhibitory effect on cancer cell proliferation was shown to be 50 to 90% for 24 hours of cell culture.
  • FIG. 22 is a graph showing the effect of suppressing proliferation of cancer cells by culturing the human colon cancer cell line HCT116 for 48 hours after treatment with puritone by concentration.
  • FIG. As shown here, it was found that the cell growth inhibition effect was 50 to 60% for 48 hours.
  • the puritone liquid was diluted to 50% in water. 1 mL of each sample dilution was added to the tube three times at each time point and each virus was tested. A negative control (water) and a positive control (70% ethanol) were included in each replicate.
  • One set of toxic control tubes was prepared in the same manner without the addition of virus. Virus was added to the tube at each time point (4 hours and 18 hours). 10 ⁇ l of Zika virus stock and 100 ⁇ l of influenza A (H5N1) viral stock were added to each tube and mixed thoroughly. The activity of the H5N1 strain was low and the volume required for the test was increased. Thus, the highest concentration of tested drug after virus addition was 90%, but Zika was 99%. The tubes were incubated at room temperature for 4 hours or 18 hours.
  • Virus (30 CCID50 / well) was added to monitor the antiviral activity (neutralization regulation) of intracellular compounds in half of the uninfected control. The plates were incubated at 5% CO 2 at 37 ⁇ 2 °C. Cultures were scored for the presence or absence of cytopathic effect (CPE) on day 3 for H5N1 and on day 6 for Zika virus. The endpoint titer of the sample (50% cell culture infectious dose, CCID50) was determined using the Reed-Muench method and the log reduction value (LRV) of the compound compared to the negative (water) control was calculated.
  • CPE cytopathic effect
  • Tables 8 and 9 below show the virucidal activity of puritone against Zicca virus and influenza A, respectively.
  • the neutralized control group showed that the virus was effectively detected in the titer assay.
  • the titer plate was valid and toxicity was not observed on the test plate.
  • influenza A H5N1
  • 70% ethanol was completely effective and the control group with no virus treatment was as expected.
  • the undiluted compound showed effective viral activity at contact times of 4 and 18 hours, while the 50% solution was effective at contact times of 18 hours, but less effective at contact times of 4 hours.
  • E. coli targeting component reported to have antibacterial efficacy (Escherichia coli), Staphylococcus brother, Les (Staphylococcus aureus), Pseudomonas rugi Ah Labor (Pseudomonas aeruginosa), Candida albicans (Candida albicans) and Salmonella typhimurium bunch was measured an antibacterial effect for help (Salmonella typhimurium).
  • Each microorganism was grown to 1,000,000 CFU / ml and added to each sample and purified water. After 24 hours and 7 days, the number of microorganisms in the plate was recovered. The results are shown in Table 10 and FIG. 23 to FIG.
  • Figure 24 shows the antimicrobial activity of puritone against Staphylococcus aureus .
  • Figure 26 shows the antimicrobial activity of puritone against Salmonella typhimurium .
  • Figure 27 shows the antimicrobial activity of puritone against Candida albicans .
  • 6-week-old ICR mice 24 rats
  • 400 ⁇ l and 800 ⁇ l of puritone were orally administered to the two groups one hour before autopsy.
  • Acetaldehyde Assay kit [BioAssay Systmes, Cat. No. EACT-100] was used to analyze the acetaldehyde content.
  • Standard and sample were added to each well of a 96-well plate in an amount of 20 ⁇ l, and then 80 ⁇ l of Working Reagent was added to each well, followed by reaction at room temperature for 30 minutes. The absorbance was then measured at 562 nm and the content of acetaldehyde was analyzed. As a control, tap water was used.
  • acetaldehyde content was high due to alcohol degradation by puritone from 0 hours to 3 hours after alcohol administration, but acetaldehyde content rapidly decreased after 3 hours.
  • Acetaldehyde Assay kit [BioAssay Systmes, Cat. No. EACT-100] was used to analyze the activity colorimetry of aldehyde dehydrogenase.
  • FIG. 29 is a graph showing the result of color analysis of activity of aldehyde dehydrogenase by puritone.
  • FIG. As shown here, after 3 hours of alcohol administration by puritone, ALDH increased and acetaldehyde, a causative agent of hangover, was decreased.
  • Puritone and Band-Aid Brand First Aid Hurt Free Antiseptic Liquid were sprayed 3-4 times daily for 15 days in an amount of 100 mg / kg per mouse total weight, respectively, on the incision sites of the puritone-treated group and the positive control group .
  • the incision was photographed at a constant distance from each group using a digital camera every day after incision, and the change of the wound was visually observed.
  • the area of the incision was measured , H & E staining, or M & T staining.
  • FIG. 30 is a photograph of a cut-off healing effect through an animal experiment of puritone, and a visual reduction of the incision area.
  • FIG. 31 is a graph showing an actual size of the incision area reduction as an incision healing effect through an animal experiment of puritone.
  • the wound area showed a tendency to decrease during the treatment period.
  • the wound size was larger in the puritanthus females than in the positive control group, but from the 2nd day, And it was confirmed that the size difference of about 1 mm was caused by the largest size difference between 6 days and 11 days from the wound. From this, it can be seen that the puritone significantly reduces the wound area.
  • Kaolinite A1 2 Si 2 O 5 ( OH) 4) 19 Bio-tight (KFe 3 (AlSi 3 O 10 ) (OH) 2) 18 ((Na, Ca) 0.3 (Al, Mg) 2 Si 4 O 10 (OH) 2n (H 2 O)) 17 Surfentin (Mg, Fe) 3 Si 2 O 5 (OH) 4 ) 12
  • Mica AB 2- 3 (X, Si ) 4 O 10 (O, F, OH) 2) 8 (Mg, Fe, Al) 3 (Al, Si) 4 O 10 (OH) 2 .4H 2 O) 4 Muscovite (KAl 2 (AlSi 3 O 10 ) (F, OH) 2 ) 3 (Mg, Fe, Al) 6 (Si, Al) 4 O 10 (OH) 8 ) 3 Brucite (Mg (OH) 2 ) 2 Illite (KAl 1.
  • the experimental animals used in the experiments have accumulated abundant test data and can be used for the interpretation and evaluation of the test results.
  • a specific pathogen member (SPF) mouse BALB / c mouse, was selected.
  • the number of animals was calculated as the minimum number sufficient to interpret the test results and divided into 6 groups according to the substance to be administered, and 8 animals per group were calculated.
  • the criteria for the calculation are 4 BALF samples for autopsy and 4 lungs for lung tissue.
  • the animal test schedule was observed at least once a day with a purifying period in the animal room where animals were tested after they were received.
  • the weight of the animals determined to be healthy during the refinement period was measured and ranked, and the test groups were randomly distributed so that the average weight of each group was uniformly distributed.
  • Each group was set up as a total of 5 groups: control group, ovarian albumin-induced control group (OVA), positive control group (Dexamethasone, Dex), 700 ⁇ l of purite and 1400 ⁇ l.
  • OVA ovarian albumin-induced control group
  • Dex positive control group
  • the experiment sensitizes OVA by intraperitoneal injection once a week for 2 weeks after the purifying period.
  • Positive control substances and puritone were orally administered in the morning for 5 days from the third week, and 5% OVA solution was administered in the afternoon.
  • the dose was orally administered to 28 [mu] l per body weight (g) of the experimental animals. After 5 days of administration, autopsy was performed the next day.
  • OVA ovalbumin
  • the first BALF was taken in tube # 1, the second, and the third BALF taken in tube # 2. After centrifugation at 3000 rpm for 5 minutes, the supernatant was transferred to No. 3, and the remaining pellet was mixed with 20 ⁇ l of PBS. After centrifugation at 3000 rpm for 5 minutes, the supernatant was discarded and the pellet and PBS (60 ⁇ l) were added and mixed. One 20 ⁇ l of the mixture was mixed with a total of 80 ⁇ l using a hematology analyzer (Hemavet 950FS, Drew Scientific Inc, Korea) And blood cell counts were analyzed.
  • Hemavet 950FS Hemavet 950FS, Drew Scientific Inc, Korea
  • FIG. 33 is a graph showing the result of neutrophil analysis of puritan BALF
  • FIG. 34 is a graph showing the results of lymphocyte analysis of BALF of purite.
  • FIG. 32 is a graph showing the results of white blood cell (WBC) analysis of puritan BALF
  • FIG. CON is a normal animal group
  • DEX is a dexamethasone treatment group which is an asthma treatment drug
  • 700 ⁇ l of purite is 700 ⁇ l treated with purite
  • 1400 of purite is treated with 1400 of purite.
  • FIG. 35 is a graph showing the results of IgE analysis of Puritone BALF. After completion of the treatment, an autopsy was performed to obtain serum, and immunoglobulin E (IgE) was confirmed. Immunoglobin is an antibody that is classified into five types of IgA, IgM, IgE, IgD and IgG. When parasite infections and irritable immune reactions occur, the amount of IgE increases sharply. Asthma is one of the irritable immune responses, and IgE is one of the indicators to check the occurrence and treatment of asthma. As shown here, the amount of IgE in the puritone treated group was dose-dependently decreased.
  • H & E staining is the most widely used staining method in tissue staining with hematoxylin and eosin staining.
  • Hematoxylin is used to stain nuclei containing a large amount of phosphoric acid in tissues.
  • Eosine binds with acidic and basic atomic groups to produce color, which stains the outer structure of cells such as cytoplasm and cell walls.
  • FIG. 36 shows changes in lung tissue due to puritone observed using H & E staining.
  • a is the normal group
  • b is the asthma induction group
  • c is the dexamethasone treatment group
  • d is the treatment group of 700 ⁇ l of purite
  • e is the treated group of 1400 ⁇ of purite.
  • e bronchiolar epithelial cells (hyperplasia)
  • bronchioles are filled with musos, and many inflammatory cells around bronchioles and vessels And infiltration was observed.
  • the dexamethasone treatment group (c) and the puritane treatment group (d and e) of the present invention inhibit the proliferation of bronchial epithelial cells, reduce the amount of musos in the bronchioles, and stimulate many inflammatory cells around the bronchioles and vessels ) was able to confirm a dose-dependent manner of infiltration.
  • polysaccharides, mucopolysaccharides, mucopolysaccharides and glycoproteins are present in the tissues.
  • the carbohydrate groups bound to these proteins are oxidized by periodic acid to produce aldehyde groups, Schiff's reagent) and is a purple-red principle.
  • Paraffin removal and hydration were carried out with 15 minutes of xylene, 1 minute of 80% alcohol, 1 minute of 90% alcohol and 1 minute of 100% alcohol.
  • the tissues were oxidized by soaking in 0.5% iodine solution for 10 minutes. After the oxidation, tap water flowing for 5 minutes was washed with water and lightly rinsed with primary distilled water for 3 minutes. After washing with water, the reaction solution was immersed in a Sip reagent for 10 minutes and then washed with running tap water for 5 minutes. After washing with water, it was stained with hematoxylin for 1 minute and 30 seconds and then rinsed with water for 10 minutes. After washing with water, the tissue was sealed by a mounting process and observed with a microscope.
  • FIG. 37 shows changes in pulmonary tissue caused by puritone using PAS staining.
  • the musculoskeleton was filled in the bronchus.
  • the dexamethasone treatment group (c) and the puritin treatment group (d and e) of the present invention It is possible to confirm the reduction.
  • OptEIA mouse ELISA was purchased from BD Biosciences. All analyzes were performed according to the manufacturer's instructions. All lung samples were prepared with protease inhibitor cocktail and lysis buffer prepared with RIPA buffer (Thermo Fisher Scientific). Lung tissue aliquots from all groups were weighed and homogenized with lysis buffer. The centrifuge was centrifuged at 8200 rpm for 15 minutes and the supernatant was collected and measured using a microplate reader (EZ Read 400, Biochrom, Cambourne, UK).
  • Asthma is a disease caused by an imbalance of Th1 and Th2 due to an irritable immune response, especially the IL-4 related to Th2.
  • FIG. 38 shows the results of observing the degree of expression of IL-4 by puritone.
  • CON is a normal animal group
  • OVA is an egg white albumin-induced control group
  • DEX is treated with dexamethasone, which is a therapeutic agent for asthma
  • 700 ⁇ l of purite is treated with 700 ⁇ l of purite
  • 1400 ⁇ l of purite is treated with 1400 ⁇ l of purite It means a group.
  • the expression of IL-4 was found to be decreased in dependence on the purite concentration.
  • the composition containing the mineral ion mixture of the present invention is safe as a human body and has anticancer, antibacterial, alcohol decomposition, skin wound healing or skin regeneration and anti-asthmatic effect, so that it is useful as a pharmaceutical, cosmetic and food composition Can be used.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Nutrition Science (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Mycology (AREA)
  • Inorganic Chemistry (AREA)
  • Dermatology (AREA)
  • Physiology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition anticancéreuse antibactérienne de dégradation d'alcool, de cicatrisation de plaie cutanée ou de régénération cutanée, et une composition anti-asthmatique comprenant un mélange d'ions minéraux en tant que principe actif. Un mélange d'ions minéraux comprenant de la biotite, de la kaolinite, de la montmorillonite, de la serpentine, du mica, du clinochlore, de la vermiculite et de la muscovite peut inhiber la prolifération de la lignée cellulaire du cancer du sein humain MDA-MB -231, de la lignée cellulaire du cancer du foie humain HepG2, de la lignée cellulaire du cancer du poumon humain A549, de la lignée cellulaire du cancer du poumon humain A549, de la lignée cellulaire du cancer du sang humain HL60, de la lignée cellulaire du cancer de la peau humaine A375, de la lignée cellulaire du cancer du rein humain RCC4 (-), et de la lignée cellulaire du cancer du côlon humain HCT116, et peut donc être utile en tant que composition anticancéreuse ; présente une excellente activité antibactérienne contre diverses bactéries ; peut dégrader l'alcool avec une très grande efficacité, atténuant ainsi rapidement la gueule de bois, et est efficace pour améliorer les fonctions hépatiques lorsqu'elle est ingérée sur une longue période de temps ; ne provoque pas d'irritation cutanée ni de cytotoxicité, est hautement stable chez l'être humain, et est efficace pour la cicatrisation des plaies cutanées et la régénération de la peau car elle agit pour former de nouveaux tissus au niveau d'une région de plaie et pour réduire les cicatrices ; et joue un rôle dans la suppression ou l'élimination de divers symptômes asthmatiques dérivés de l'ovalbumine, restreint la prolifération de globules blancs, de neutrophiles et de lymphocytes dans le liquide de lavage broncho-alvéolaire (BALF) et le sérum, inhibe la prolifération des cellules épithéliales bronchiques, et réduit le mucus dans le bronchiole et l'infiltration de nombreuses cellules inflammatoires autour de la bronchiole et des vaisseaux en fonction de la dose. De plus, la composition a induit la réduction de la cytokine IL-4 liée aux cellules Th2. Par conséquent, une composition comprenant le mélange d'ions minéraux de la présente invention peut être utile en tant que composition pharmaceutique, cosmétique et alimentaire, étant donné qu'il s'agit d'un matériau naturel sans danger pour le corps humain et qui présente des effets anticancéreux, antibactériens, de dégradation d'alcool, de cicatrisation de plaie cutanée ou de régénération cutanée, et anti-asthmatiques.
PCT/KR2018/015205 2017-12-01 2018-12-03 Composition anticancéreuse, antibactérienne de dégradation d'alcool, de cicatrisation de plaie cutanée, de régénération cutanée ou anti-asthmatique comprenant un mélange d'ions minéraux Ceased WO2019108049A2 (fr)

Applications Claiming Priority (14)

Application Number Priority Date Filing Date Title
KR20170164585 2017-12-01
KR10-2017-0164585 2017-12-01
KR10-2018-0005734 2018-01-16
KR20180005734 2018-01-16
KR10-2018-0086173 2018-07-24
KR1020180086173A KR101996383B1 (ko) 2017-12-01 2018-07-24 퓨리톤을 유효성분으로 포함하는 항암용 조성물
KR1020180107032A KR101963614B1 (ko) 2018-09-07 2018-09-07 미네랄 이온 혼합물을 포함하는 알콜분해용 조성물
KR1020180107033A KR101973198B1 (ko) 2018-01-16 2018-09-07 미네랄 이온 혼합물을 포함하는 천식 예방 및 치료용 조성물
KR10-2018-0107032 2018-09-07
KR10-2018-0107033 2018-09-07
KR10-2018-0135373 2018-11-06
KR1020180135373A KR102022671B1 (ko) 2018-11-06 2018-11-06 미네랄 이온 혼합물을 포함하는 피부상처 치유 또는 피부재생용 조성물
KR1020180152879A KR102037431B1 (ko) 2018-11-30 2018-11-30 미네랄 이온 혼합물을 포함하는 항균용 조성물 및 이를 포함하는 항바이러스제
KR10-2018-0152879 2018-11-30

Publications (2)

Publication Number Publication Date
WO2019108049A2 true WO2019108049A2 (fr) 2019-06-06
WO2019108049A3 WO2019108049A3 (fr) 2019-08-08

Family

ID=66665149

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2018/015205 Ceased WO2019108049A2 (fr) 2017-12-01 2018-12-03 Composition anticancéreuse, antibactérienne de dégradation d'alcool, de cicatrisation de plaie cutanée, de régénération cutanée ou anti-asthmatique comprenant un mélange d'ions minéraux

Country Status (1)

Country Link
WO (1) WO2019108049A2 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112441825A (zh) * 2019-08-28 2021-03-05 延世大学原州产学合作团 用于缓解或改善炎症的陶瓷组合物及其制备方法
CN113952462A (zh) * 2021-11-18 2022-01-21 中南大学湘雅三医院 合成类纤维蛇纹石纳米材料的新用途
US12171841B1 (en) 2024-07-19 2024-12-24 Imam Mohammad Ibn Saud Islamic University Synthesis and characterization of glauconite-based silicate nanorods as anticancer agent

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7217853B2 (en) * 2002-05-24 2007-05-15 Corium International, Inc. Composition for cushions, wound dressings and other skin-contacting products
KR100992216B1 (ko) * 2008-04-22 2010-11-04 순천향대학교 산학협력단 창상 치료용 미네랄 조성물
KR20100025435A (ko) * 2008-08-27 2010-03-09 순천향대학교 산학협력단 알레르기성 염증 억제 조성물
US8465731B2 (en) * 2010-03-12 2013-06-18 Elc Management, Llc Probiotic color cosmetic compositions and methods
KR20170030245A (ko) * 2015-09-09 2017-03-17 이대훈 필로규산염광물을 이용한 천연미네랄 제조방법

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN112441825A (zh) * 2019-08-28 2021-03-05 延世大学原州产学合作团 用于缓解或改善炎症的陶瓷组合物及其制备方法
CN113952462A (zh) * 2021-11-18 2022-01-21 中南大学湘雅三医院 合成类纤维蛇纹石纳米材料的新用途
US12171841B1 (en) 2024-07-19 2024-12-24 Imam Mohammad Ibn Saud Islamic University Synthesis and characterization of glauconite-based silicate nanorods as anticancer agent
US12257315B1 (en) 2024-07-19 2025-03-25 Imam Mohammad Ibn Saud Islamic University Cancer treatment method with nanocomposite

Also Published As

Publication number Publication date
WO2019108049A3 (fr) 2019-08-08

Similar Documents

Publication Publication Date Title
WO2016060525A1 (fr) Composition contenant un extrait ou une fraction d'une plante du genre justicia
WO2019108049A2 (fr) Composition anticancéreuse, antibactérienne de dégradation d'alcool, de cicatrisation de plaie cutanée, de régénération cutanée ou anti-asthmatique comprenant un mélange d'ions minéraux
WO2017048028A1 (fr) Nouveau peptide antimicrobien dérivé du peptide myxinidine, et son utilisation
WO2019103541A1 (fr) Composition anti-inflammatoire comportant une nanostructure de graphène
WO2020091440A9 (fr) Composition permettant d'améliorer l'endommagement de la barrière cutanée et/ou de soulager l'inflammation cutanée, contenant de l'acide 3,5-dicaféoylquinique en tant que principe actif
WO2013172525A1 (fr) Produits cosmétiques, produits pharmaceutiques et composition alimentaire contenant des morceaux ou un extrait d'yeux de poisson
WO2017179931A1 (fr) Composition pharmaceutique pour prévenir ou traiter une maladie respiratoire comprenant un extrait de justicia procumbens l.
WO2015037778A1 (fr) Composition contenant un composé de lignane comme principe actif pour prévenir ou traiter un cancer
WO2024123024A1 (fr) Composition contenant un extrait de centipeda minima pour la prévention et le traitement de l'inflammation et des maladies auto-immunes et son procédé de fabrication
WO2014163298A1 (fr) Procédé d'extraction destiné à séparer un extrait de résidus de noni présentant un fort effet de protection de la peau et composition le contenant destinée à protéger la peau et à traiter et prévenir le vieillissement de la peau
WO2023182540A1 (fr) Composition pour prévenir et atténuer une maladie virale
WO2020067748A1 (fr) Composition ayant un effet anti-stress, antidépresseur ou anxiolytique comprenant au moins un composé choisi dans le groupe constitué par l'undécanal, le dodécanal, et des sels pharmaceutiquement acceptables de ces derniers en tant que principe actif
WO2020085826A1 (fr) Composition pour soulager une irritation de la peau induite par des facteurs de pollution environnementaux ou pour la protection de la peau, contenant comme principe actif un extrait de noix de muscade ou du macelignane
WO2020218890A1 (fr) Composition consistant en un extrait d'actinidia polygama destiné à attenuer des lésions cutanées ou hydrater la peau
WO2020032365A1 (fr) Composition, comprenant un composé de ginsénoside, pour la prévention ou le traitement d'une maladie inflammatoire médiée par des inflammasomes
WO2021182864A1 (fr) Composition topique comprenant un extrait d'herbes combinées comprenant longanae arillus pour le traitement ou le soulagement de l'ulcère cutané et son utilisation
WO2020027534A1 (fr) Composition comprenant de la punicalagine permettant d'inhiber l'activité de par2
WO2015037855A1 (fr) Composition comprenant un extrait d'herbes combinées comprenant de l'acanthopanax koreanum naka et du crinum asiaticum var. japonicum présentant une activité de prévention de la calvitie et une activité de stimulation de la croissance capillaire
WO2016010340A1 (fr) Composition pour prévenir et traiter l'inflammation ou les maladies allergiques contenant un extrait de gynura procumbens en tant que principe actif, et son utilisation
WO2013025004A2 (fr) Composition pharmaceutique pour prévenir ou traiter le cancer comprenant un extrait de radix lithospermi seu arnebiae en tant que substance active
WO2024144265A1 (fr) Composition pour la prévention ou le traitement de maladies respiratoires induites par les poussières fines contenant un extrait de lonicera japonica comme principe actif
WO2018106009A1 (fr) Composition comprenant un extrait de feuille d'arbre d'érable ou des fractions de ce dernier destinée à prévenir ou à traiter des maladies oculaires inflammatoires
WO2023003292A1 (fr) Composition pour la prévention, l'amélioration ou le traitement de plaies ou d'inflammations de la peau
WO2013024960A1 (fr) Composition médicale contenant un extrait de stauntonia hexaphylla
EP4117698A1 (fr) Composition topique comprenant un extrait d'herbes combinées comprenant longanae arillus pour la régénération cutanée et le traitement ou le soulagement de plaie cutanée et son utilisation

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 18883605

Country of ref document: EP

Kind code of ref document: A2

32PN Ep: public notification in the ep bulletin as address of the adressee cannot be established

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO RULE 112(1) EPC (EPO FORM 1205A DATED 01/02/2021)

122 Ep: pct application non-entry in european phase

Ref document number: 18883605

Country of ref document: EP

Kind code of ref document: A2